Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Manns, Michael

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. [electronic resource] - Lancet (London, England) Aug 2014 - 414-26 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1474-547X

10.1016/S0140-6736(14)60538-9 doi


Adolescent
Adult
Aged
Antiviral Agents--administration & dosage
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Female
Genotype
Hepacivirus--genetics
Hepatitis C, Chronic--drug therapy
Heterocyclic Compounds, 3-Ring--administration & dosage
Humans
Interferon alpha-2
Interferon-alpha--administration & dosage
Male
Middle Aged
Polyethylene Glycols--administration & dosage
Recombinant Proteins--administration & dosage
Ribavirin--administration & dosage
Simeprevir
Sulfonamides--administration & dosage
Treatment Outcome